


FAIRE LE LIEN AVEC L'INFLAMMATION DE TYPE 2

ETAT DES LIEUX


De récentes recherches scientifiques ont montré qu'une inflammation de type 2 excessive, c'est à dire une réponse hyperactive du système immunitaire, serait à l'origine de différentes maladies atopiques, inflammatoires et chroniques.^[1-3]



IMPACT D'UNE INFLAMMATION DE TYPE 2 EXCESSIVE CHEZ LES PATIENTS

1 Certaines personnes vivent avec une ou plusieurs maladies inflammatoires de type 2 coexistantes.

Le manque de sensibilisation à l'inflammation de type 2 et aux maladies inflammatoires associées peut entraîner une incompréhension des patients sur les liens qu'elles peuvent avoir entre elles, et les options de prise en charge disponibles.^[4]



2 De nombreux patients vivent avec des symptômes non-contrôlés, en particulier ceux qui présentent des formes modérées à sévères de maladies inflammatoires de type 2.

Jusqu'à
75%

des adultes atteints de DA modérée à sévère ont une maladie insuffisamment contrôlée.^[13-17]

Jusqu'à
45%

des personnes asthmatiques sous traitement en Europe, souffrent encore d'une maladie non contrôlée.^[18]

Jusqu'à
79%

des personnes atteintes de PNS, présentent une récidive dans les douze ans suivant l'intervention chirurgicale, en raison d'une maladie non contrôlée.^[19]

3 Les conséquences sur la vie quotidienne de nombreux patients sont d'autant plus importantes qu'à la sévérité de la maladie s'ajoute la présence de plusieurs maladies coexistantes.^[4,5]



**Environ
45%**

des adolescents atteints de DA subissent un impact négatif sur leur vie scolaire à cause de la maladie.^[20]



**Jusqu'à
50%**

des personnes atteintes de DA subissent un impact négatif sur leur vie scolaire à cause de la maladie.^[21]



**Jusqu'à
70%**

des personnes atteintes de PNS souffrent d'une perte de qualité de sommeil.^[22,23]

RÉFÉRENCES

1. N. A. Gandhi, B. L. Bennett and N. M. Graham, "Targeting key proximal drivers of type 2 inflammation in disease," *Nature Reviews Drug Discovery*, vol. 15, no. 1, pp. 35-50, 16 October 2016.
2. S. Carr, E. Chan, and W. Watson, "Eosinophilic esophagitis," *Allergy, Asthma & Clinical Immunology*, vol. 14, no. Suppl 1, p. 58, 2018.
3. J. W. Steinke and J. M. Wilson, "Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances," *Journal of Asthma and Allergy*, vol. 9, pp. 37-43, 2016.
4. Staikuniene J, et al. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. *Medicina (Kaunas)* 2008; 44(4):257-265.
5. J.I. Silverberg, J.M. Gelfand, and D.J. Margolis, "Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults," *Ann Allergy Asthma Immunol*, vol. 121, no. 5, pp. 604-612, 2018.
6. D. E. Shaw, A. R. Sousa and S. J. Fowler, "Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort," *European Respiratory Journal*, vol. 46, no. 5, pp. 1308-1321, 2015.
7. E. Heffler, F. Blasi and M. Latorre, "The Severe Asthma Network in Italy: Findings and Perspectives," *Journal of Allergy and Clinical Immunology*, vol. 7, no. 5, pp. 1462-1468, 2018.
8. E. Simpson, E. Guttman-Yassky and D. Margolis, "Chronicity, comorbidity, and life course impairment in atopic dermatitis: Insights from a cross-sectional study in US adults," in 25th European Academy of Dermatology and Venereology (EADV) Congress, Vienna, 2016.
9. A. Khan, G. Vandeplas and T. Huynh, "The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European crosssectional study of chronic rhinosinusitis patients with and without nasal polyps," *Rhinology*, vol. 57, no. 1, pp. 32-42, 2019.
10. J. C. Staniorski, C.P.E. Price, and A.R. Weibman, "Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population," *Int Forum Allergy Rhinol*, vol. 8, no. 4, pp. 495-503, 2018.
11. S. Maio, S. Baldacci and M. Bresciani, "RItA: The Italian severe/uncontrolled asthma registry," *Allergy*, vol. 73, no. 3, pp. 683-695, 2018.
12. C. Philpott, S. Erskine and C. Hopkins, "Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study," *Respiratory Research*, vol. 19, p. 129, 2018.
13. M. Iskedjian, C. Piwko and N. Shear, "Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence," *Am J Clin Dermatol*, vol. 5, no. 4, pp. 267-279, 2004.
14. J. Cury Martins, C. Martins and V. Aoki, "Topical tacrolimus for atopic dermatitis (Review)," *The Cochrane Collaboration*. Published by John Wiley & Sons, Ltd., 2016.
15. S. Meggitt, J. Gray and N. Reynolds, "Azathioprine dosed by thiopurine methyltransferase activity for moderate to severe atopic eczema: a double-blind, randomised controlled trial," *Lancet*, vol. 367, no. 9513, pp. 839-846, 2006.
16. D. Ashcroft, P. Dimmock and R. Garside, "Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials," *BMJ*, vol. 330, no. 7490, pp. 516-522, 2005.
17. M. Schram, E. Roekevisch and M. Leeflang, "A randomized trial of methotrexate versus azathioprine for severe atopic eczema," *J Allergy Clin Immunol*, vol. 128, no. 2, pp. 353-359, 2011.
18. D. Price, M. Fletcher and T. Van Der Molen, "Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey," *NPJ Primary Care Respiratory Medicine*, vol. 24, p. 14009, 2014.
19. P. Gevaert, L. Calus, and N. van Bruaene, "Allergic Sensitization, High Local IL-5 and IgE Predict Surgical Outcome 12 Years after Endoscopic Sinus Surgery for Chronic Rhinosinusitis with Nasal Polypsis," *J Allergy Clin Immunol*, vol. 135, no. 2, p. AB238, 2015.
20. T. Zuberbier , S. Orlow and A. Paller, "Patient perspectives on the management of atopic dermatitis," *Journal of Allergy and Clinical Immunology*, vol. 118, no. 1, pp. 226-232, 2006.
21. C. Rand, R. Wright and M. Cabana, "Mediators of asthma outcomes," *J Allergy Clin Immunol*, vol. 129, no. 301, pp. 136-141, 2012.
22. A. Shedd, "Impact of nasal congestion on quality of life and work, productivity in allergic rhinitis: findings from a large online survey," *Treat Respir Med*, vol. 4, no. 6, pp. 439-46, 2005.
23. E. Serrano, F. Neukirch and C. Pribil , "Nasal polyposis in France: impact on sleep and quality of life," *the Journal of Laryngology & Otology*, vol. 119, no. 8, pp.543-549, 2005.